Axsome Therapeutics, Inc. (AXSM) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high gross margin ⢠Negative FCF ⢠High debt / rich valuation Axsome combines very high gross margins and sizeable cash reserves with persistent large operating losses, negative free cash flow, meaningful leverage, and an elevated market valuation that depends on substantial nearâterm improvement in profitability and cash generation.
Price Behavior
Key Price Behavior Insights: ⢠Strong downtrend ⢠Oversold momentum ⢠Mean-reversion risk Support Level: $154 Resistance Level: $169; $183â$186 Stock is in a clear short-term downtrendâdown ~14.5% over the last month, trading well below the last month 21-day moving average (~$169) with RSI ~26 (oversold), support near $154 and resistance at ~$169 and $183â186; wait for RSI >30 or a sustained close above $169 for confirmation.
Sentiment & News
Key News Insights: ⢠Rapid revenue growth ⢠Continued losses ⢠Patent settlement Axsome's Auvelity-driven commercial surge (+74% to $507M) lifted 2025 revenue +66% to $638.5M, yet the company remains loss-making with mixed analyst views, a SUNOSI patent settlement and notable insider selling.
AI Summary
Axsome has moved from a binary clinical bet to a revenue-driven commercial company as Auvelity scales, but the investment now hinges on stabilization of grossâtoânet realized pricing and delivering cashâflow positivity by midâ2026 â failure to do so would likely force dilutive financing and rapidly compress the current high valuation; monitor realized net revenue per prescription, GTN trajectory, NDA acceptances (AXSâ12/AXSâ05), and cash burn vs plan.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |